Defining key parameters of therapeutic activity using mouse cancer neoepitopes

2025•Journal of Immunology

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity

2023•Nature

Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope

2021•Nature Communications

Mass spectrometry–driven exploration reveals nuances of neoepitope-driven tumor rejection

2019•Cancer Immunology Research

CD11c+ MHCIIlo GM-CSF-bone marrow-derived dendritic cells act as antigen donor cells and as antigen presenting cells in neoepitope-elicited tumor immunity against a mouse fibrosarcoma

2018•Cancer Immunology, Immunotherapy

Neoepitopes as cancer immunotherapy targets: key challenges and opportunities

2017•Immunotherapy

Tumor Control Index as a new tool to assess tumor growth in experimental animals

2017•Journal of Immunological Methods